Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Selpercatinib/vandetanib

Lack of efficacy and drug resistance

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Pishdad R, et al. RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report. Frontiers in Oncology 14: Feb 2024. Available from: URL: https://dx.doi.org/10.3389/fonc.2024.1360492 Pishdad R, et al. RET gene fusion and emergent Selpercatinib resistance in a calcitonin-rich neuroendocrine carcinoma: a case report. Frontiers in Oncology 14: Feb 2024. Available from: URL: https://​dx.​doi.​org/​10.​3389/​fonc.​2024.​1360492
Metadaten
Titel
Selpercatinib/vandetanib
Lack of efficacy and drug resistance
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56573-4

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Multiple drugs

Case report

Nitroglycerin

Case report

AZD-1222

Case report

Dexamethasone